← Back to Search

Educational App for Hepatitis C

N/A

Recruiting

Led By Yu-Hsiang Hsieh, PhD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

HCV positive without HCV RNA information

18 years or older

Must not have

Younger than 18 years of age

Unable to provide informed consent

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 28 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will test the impact of a personalized educational app on people's knowledge and motivation related to hepatitis C care.

Who is the study for?

This trial is for adult patients at Johns Hopkins Hospital's Emergency Department who have tested positive for Hepatitis C but don't yet have HCV RNA testing information. It excludes minors, those unable to consent, prisoners, critically ill individuals, and patients with altered mental status.

What is being tested?

The study tests an educational app designed to improve understanding of Hepatitis C among ED patients. The app provides personalized liver health information and aims to enhance patient knowledge and motivation regarding their care continuum from diagnosis through treatment.

What are the potential side effects?

Since this trial involves the use of an educational app rather than a medical intervention or drug, traditional physical side effects are not expected. However, participants may experience stress or anxiety related to learning about their condition.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am positive for hepatitis C but don't have RNA details.

Select...

I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am under 18 years old.

Select...

I am unable to understand and give consent for treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 28 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~28 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Linkage to care rate (days)

Secondary study objectives

Change in HCV knowledge as assessed by True/False survey questions

Change in level of motivation to receive HCV care as assessed by a Likert Scale

Change in perceived barriers to HCV care as assessed by a Likert Scale

+3 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Patient-Centered Electronic App GroupExperimental Treatment1 Intervention

Patients assigned to the intervention group will receive individualized reports regarding patients' HCV disease progress/liver fibrosis staging by a Fibrosis-4 score using the personalized HCV educational app. The individualized report will also include comprehensive knowledge to fill the gap on general HCV information, natural history of the disease, and care and treatment, if there is any, as well as level of interest in receiving HCV care based on patients' response to the short survey questionnaires on the tablet. Patients will also receive the investigators' HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore. Patients will receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.

Group II: Reference GroupActive Control1 Intervention

Patients assigned to the reference group will receive the investigators' current 'static' standard of care HCV program pamphlet regarding HCV infection and disease progression, treatment, as well as information regarding clinics available for HCV care in Baltimore City. Patients will also receive standard of care, routine HCV LTC services from the investigators' ED HCV LTC program staff.

0 / 4Eligibility criteria met